Sepsis Set Back: AstraZeneca CytoFab Development Will Be Delayed Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will conduct a 21-month Phase II study prior to initiating a Phase III trial.
You may also be interested in...
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
AstraZeneca Releases Toprol-XL “Authorized” Generic Following Sandoz Launch
25 mg dosage strength accounts for 20% of Toprol-XL sales.